Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

News headlines Vertex Pharmaceuticals (VRTX) is gaining attention with promising developments in kidney treatments and solid earnings growth, although concerns linger about its reliance on cystic ...

EHA: Vertex, CRISPR build case for gene-editing drug A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...

BofA lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $563 from $565 and keeps a Buy rating on the shares. The firm, which expects steady growth for the cystic fibrosis franchise in ...

Abstract: An efficient implicit representation of an n-vertex graph G in a family $\mathcal{F}$ of graphs assigns to each vertex of G a binary code of length O(log n) so that the adjacency between ...

Abstract: Anomaly detection is a fundamental task in hyperspectral image (HSI) processing. However, most existing methods rely on pixel feature vectors and overlook the relational structure ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Production efficiency is a point where ...

Sales from two of Vertex Pharmaceuticals’ newest products appear to have dampened an earnings report that otherwise met or slightly exceeded expectations on Wall Street. Vertex recorded a little over ...